Gut Bacteria Influences Immunotherapy Response in Skin Cancer Patients
Highlights
- PD1 is a protein on the surface of T cells, the immune system's specialized attack cells, that shuts down immune response.
- Anti-PD1 drugs use an antibody to block activation of PD1.
- Anti-PD1 immunotherapy is effective for many, but not all, melanoma patients.
- Patients who responded to the immunotherapy, had a greater diversity of types of gut bacteria.
Gut bacteria has an influence in a major form of immunotherapy given to patients with melanoma.
Analysis of 113 fecal samples of patients with metastatic melanoma or skin cancer found that those who responded to a PD1 checkpoint inhibitor had a greater diversity of gut bacteria and larger volumes of a specific type of bacteria than those who did not respond.
‘Those who responded to a PD1 checkpoint inhibitor for melanoma had a greater diversity of gut bacteria and larger volumes of a specific type of bacteria.’
This connection between a person's microbiome - trillions of bacteria harbored to varying degrees in the human body and immune system could have major implications for cancer prognosis and treatment.
"Anti-PD1 immunotherapy is effective for many, but not all, melanoma patients and responses aren't always durable," said Jennifer Wargo, M.D., associate professor of Melanoma Medical Oncology.
"Our findings point to two potential impacts from additional research -- analyzing the diversity and composition of the microbiome to predict response to immunotherapy and modulating the gut microbiome to enhance treatment," said Wargo, senior researcher on the project.
Anti PD-1 Immunotherapy
PD1 is a protein on the surface of T cells, the immune system's specialized attack cells, that shuts down immune response. Anti-PD1 drugs use an antibody to block activation of PD1 by PD-L1, a ligand found on tumors and surrounding cells.
"Evidence from preclinical research had previously indicated a relationship between solid tumors, immune response, and the microbiome. Our study was the first of its type to look at the relationship between the microbiome and immunotherapy response in patients," said Vancheswaran Gopalakrishnan, first author and doctoral student at The University of Texas Health Science Center at Houston School of Public Health.
Gopalakrishnan, Wargo and colleagues examined oral and gut microbiome samples from 228 patients with metastatic melanoma. While no differences in response were found in connection with the oral samples, the 113 fecal samples told another story. Gopalakrishnan said the team conducted 16S rRNA sequencing, an analysis of the presence of 16S ribosomal RNA used to identify bacteria.
Among the 93 patients treated with anti-PD1 immune checkpoint blockade, the researchers had gut microbiome samples from 30 responders and 13 non-responders. They found a greater diversity of types of bacteria in the responders' microbiomes.
The researchers also conducted immune profiling before treatment for the presence of important immune system cells in the tumors. Responders had significantly increased immune infiltrates in their tumors, including the presence of CD8+ killer T cells, correlated to the abundance of a specific bacterium.
"The microbiome is highly targetable in a variety of ways," Gopalakrishnan said, including by diet, probiotics to boost the presence of helpful bacteria, antibiotics or by fecal transplants.
Reference
- Vancheswaran Gopalakrishnan et al., Gut bacteria associated with cancer immunotherapy response in melanoma, ASCO-Society for Immunotherapy in Cancer, Meeting (2017).
Source: Medindia
Cite this Article ⇣⇡
Please use one of the following formats to cite this article in your essay, paper or report:
-
APA
Julia Samuel. (2017, February 22). Gut Bacteria Influences Immunotherapy Response in Skin Cancer Patients. Medindia. Retrieved on Nov 14, 2024 from https://www.medindia.net/news/healthwatch/gut-bacteria-influences-immunotherapy-response-in-skin-cancer-patients-168037-1.htm.
MLA
Julia Samuel. "Gut Bacteria Influences Immunotherapy Response in Skin Cancer Patients". Medindia. Nov 14, 2024. <https://www.medindia.net/news/healthwatch/gut-bacteria-influences-immunotherapy-response-in-skin-cancer-patients-168037-1.htm>.
Chicago
Julia Samuel. "Gut Bacteria Influences Immunotherapy Response in Skin Cancer Patients". Medindia. https://www.medindia.net/news/healthwatch/gut-bacteria-influences-immunotherapy-response-in-skin-cancer-patients-168037-1.htm. (accessed Nov 14, 2024).
Harvard
Julia Samuel. 2017. Gut Bacteria Influences Immunotherapy Response in Skin Cancer Patients. Medindia, viewed Nov 14, 2024, https://www.medindia.net/news/healthwatch/gut-bacteria-influences-immunotherapy-response-in-skin-cancer-patients-168037-1.htm.